URI
URI Label
Revisions
Add to List
Edit Entry
Export:
XML
- November 2017 (1)
- July 2017 (1)
- February 2017 (1)
- January 2017 (2)
- May 2016 (1)
- April 2016 (1)
- December 2015 (1)
- November 2015 (2)
- August 2015 (1)
- June 2015 (1)
- May 2015 (3)
- April 2015 (1)
- January 2015 (1)
- December 2014 (1)
- November 2014 (2)
- August 2014 (4)
- July 2014 (2)
- June 2014 (3)
- May 2014 (1)
- April 2014 (3)
- March 2014 (2)
- February 2014 (2)
- January 2014 (1)
- December 2013 (2)
- November 2013 (3)
- September 2013 (1)
- August 2013 (1)
- July 2013 (2)
- June 2013 (2)
- April 2013 (1)
- March 2013 (1)
- February 2013 (2)
- January 2013 (1)
- December 2012 (2)
- November 2012 (1)
- September 2012 (2)
- June 2012 (2)
- April 2012 (4)
- March 2012 (2)
- March 2012 (2)
- January 2012 (3)
- 3D7 IC50 Avery Lab (3)
- AstraZeneca (2)
- MetID (3)
- Potencies GSK (1)
- Potencies Guy (1)
- Syngene (8)
- UCSD (1)
- Biology (37)
- DMPK (2)
- Dundee (4)
- GSH-EE - Chapman Lab (2)
- GSK PRR Assay (1)
- Imperial DGFA (1)
- Kirk Lab (5)
- Metabolism (1)
Show/Hide Keys
(Data originally posted in Similarity of Series 4 Compounds to KAI407 since relevant to comparison with Novartis compound KAI407)
As part of an evaluation of the mechanism of action of OSM Series 4, two inherited compounds MMV669844 and MMV670944 were evaluated vs Pb liver schizonts. The Novartis imidazopyrazines are known to be active vs. PI4K, not PfATP4, and are active against liver schizonts. The two Series 4 triazolopyrazines showed weak activity (data attached), i.e. at a level lower than would be expected based on their blood potency. These data support the hypothesis that the Novartis compounds and OSM Series 4 have distinct mechanisms of action.
(These are the same compounds as those evaluated for hERG hERG Data for MMV669844 and MMV670944)
(Data originally obtained from Paul Willis Feb 1st 2014)
(Post - MHT)